Chronic Kidney Disease
📧 Sign up to get email alerts when something new happens for Chronic Kidney Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-03EMA Authorised: NeoRecormon (epoetin beta) — Roche Registration GmbH
NeoRecormon (epoetin beta) has been authorised by the EMA for related indications in chronic kidney failure, anemia, cancer, and autologous …
-
EMA approval · 2026-06-11EMA Authorised: Edistride (dapagliflozin propanediol monohydrate) — AstraZeneca AB
Edistride, containing dapagliflozin propanediol monohydrate, has been authorised for treatment in type 2 diabetes, systolic heart failure, h…
-
EMA approval · 2026-04-22EMA Authorised: Forxiga (dapagliflozin propanediol monohydrate) — AstraZeneca AB
EMA authorised Forxiga (dapagliflozin propanediol monohydrate) for type 2 diabetes mellitus, heart failure (systolic), and chronic kidney di…
-
EMA approval · 2026-04-10EMA Authorised: Evrenzo (roxadustat) — Astellas Pharma Europe B.V.
EMA authorised Evrenzo (roxadustat) for the treatment of anemia associated with chronic kidney disease.
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approves Lupin's original application for dapagliflozin tablets (generic), enabling market entry for the SGLT2 inhibitor.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Cipla USA Inc.)
FDA approved Cipla USA Inc.'s generic dapagliflozin (ANDA 211535) as an original application. The approval makes a generic version of dapagl…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Ascend Laboratories, LLC)
FDA approved the original generic application for dapagliflozin, enabling a generic version of the SGLT2 inhibitor used for type 2 diabetes …
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Sandoz Inc)
FDA approves Sandoz's generic dapagliflozin under Original Application. The approval makes a generic version available for the same indicati…
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Florida Pharmaceutical Products, LLC)
FDA approved the Original Application (ANDA) for dapagliflozin from Florida Pharmaceutical Products, LLC.
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Macleods Pharmaceuticals Limited)
FDA approves the generic dapagliflozin from Macleods Pharmaceuticals Limited under an Original Abbreviated New Drug Application (ANDA).
-
FDA approval · 2026-04-06FDA Approved: DAPAGLIFLOZIN — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original ANDA for dapagliflozin, enabling a generic version of the diabetes medication to rea…
-
EMA approval · 2026-03-24EMA Authorised: Vafseo (vadadustat) — Medice Arzneimittel Pütter GmbH & Co. KG
The EMA authorised vadadustat (brand Vafseo) for the treatment of anemia associated with chronic kidney disease in the EU.
-
EMA approval · 2026-03-24EMA Authorised: Jardiance (empagliflozin) — Boehringer Ingelheim International GmbH
EMA authorised Jardiance (empagliflozin) in the European Union for type 2 diabetes mellitus, heart failure, and chronic kidney disease, unde…
-
EMA approval · 2026-03-24EMA Authorised: Velphoro (sucroferric oxyhydroxide) — Vifor Fresenius Medical Care Renal Pharma France
The EMA authorized Velphoro (sucroferric oxyhydroxide) for the treatment of hyperphosphatemia in patients with chronic kidney disease on ren…
-
EMA approval · 2026-03-13EMA Authorised: Edistride (dapagliflozin propanediol monohydrate) — AstraZeneca AB
The European Medicines Agency authorised Edistride, a dapagliflozin propanediol monohydrate medicine by AstraZeneca, for type 2 diabetes mel…
-
EMA approval · 2026-03-02EMA Authorised: Retacrit (epoetin zeta) — Pfizer Europe MA EEIG
EMA authorised Retacrit (epoetin zeta) as a biosimilar epoetin for the treatment of anemia in chronic kidney disease and cancer, among other…
-
EMA approval · 2026-01-26EMA Authorised: Dapagliflozin Viatris (dapagliflozin) — Viatris Limited
EMA authorised Dapagliflozin Viatris for type 2 diabetes mellitus, heart failure, and chronic kidney disease, with Viatris Limited as the ma…
-
EMA approval · 2026-01-16EMA Authorised: Kerendia (Finerenone) — Bayer AG
The European Medicines Agency authorised Kerendia (finerenone) from Bayer AG for the treatment of chronic kidney disease in adults with type…
-
EMA approval · 2026-01-13EMA Authorised: Aranesp (darbepoetin alfa) — Amgen Europe B.V.
EMA authorised Aranesp (darbepoetin alfa) for anemia associated with cancer and chronic kidney disease.
-
FDA approval · 2026-01-08FDA Approved: FUROSEMIDE — Original Application (Micro Labs Limited)
FDA approved the original application for furosemide from Micro Labs Limited.
-
FDA approval · 2026-01-07FDA Approved: METOLAZONE — Supplemental Application (Method Pharmaceuticals, LLC)
The FDA approved a supplemental application for METOLAZONE submitted by Method Pharmaceuticals, LLC.
-
FDA approval · 2025-12-22FDA Approved: FUROSCIX — Supplemental Application (scPharmaceuticals Inc.)
The FDA approved a supplemental application for FUROSCIX (furosemide injection 80 mg/10 mL) from scPharmaceuticals Inc.
-
EMA approval · 2025-11-06EMA Authorised: Xoanacyl (ferric citrate coordination complex) — Averoa
EMA authorised Xoanacyl, a ferric citrate coordination complex, for the treatment of iron deficiency and to manage hyperphosphatemia in chro…
-
FDA approval · 2025-10-27FDA Approved: SEVELAMER CARBONATE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved sevelamer carbonate (generic) from Zydus Pharmaceuticals USA Inc. as an original application. The approval covers treatment of …
-
FDA approval · 2025-10-16FDA Approved: FERABRIGHT — Original Application (Azurity Pharmaceuticals, Inc.)
FERABRIGHT (ferumoxytol) has FDA approval under its Original Application filed by Azurity Pharmaceuticals, Inc. for the treatment of iron de…